Bellevue Group Ag Adaptive Biotechnologies Corp Transaction History

Bellevue Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$6.26 - $9.34 $2 Million - $2.98 Million	-319,489 Reduced 9.74%	2,960,131 $22.6 Million
Q3 2022 Nov 14, 2022	SELL	$6.5 - $12.67 $1.69 Million - $3.29 Million	-259,435 Reduced 7.33%	3,279,620 $23.4 Million
Q2 2022 Aug 11, 2022	BUY	$6.4 - $14.73 $2.52 Million - $5.8 Million	393,762 Added 12.52%	3,539,055 $28.6 Million
Q1 2022 May 13, 2022	BUY	$10.12 - $28.9 $11.9 Million - $34 Million	1,176,862 Added 59.79%	3,145,293 $43.7 Million
Q4 2021 Feb 10, 2022	BUY	$25.17 - $36.85 $15.9 Million - $23.3 Million	632,408 Added 47.34%	1,968,431 $55.2 Million
Q3 2021 Nov 12, 2021	BUY	$30.02 - $39.87 $11.2 Million - $14.9 Million	373,671 Added 38.83%	1,336,023 $45.4 Million
Q2 2021 Aug 12, 2021	BUY	$32.22 - $44.59 $31 Million - $42.9 Million	962,352 New	962,352 $39.3 Million

202

146M

68.8K

42.5K

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $849M
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.